We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
In This Issue of JAMA |

Highlights FREE

JAMA. 2015;314(12):1197-1199. doi:10.1001/jama.2014.11991.
Text Size: A A A
Published online


Safe and effective treatments for agitation among patients with Alzheimer disease are lacking. In a 10-week, randomized, placebo-controlled study that enrolled 220 patients with probable Alzheimer disease and clinically significant agitation, Cummings and colleagues found that the combination of dextromethorphan and quinidine demonstrated clinically relevant efficacy for agitation and was generally well-tolerated. In an Editorial, Ballard and colleagues discuss pharmacologic management of agitation among patients with dementia.

Strategies to improve adoption of healthful lifestyle behaviors among patients at risk of cardiovascular events are needed. Chow and colleagues assessed the effect of lifestyle-focused semipersonalized mobile phone text messages on cardiovascular risk factors in a randomized trial that enrolled 710 patients with coronary heart disease (CHD). The authors report that compared with usual care, use of the text messaging program, which provided advice, motivational reminders, and behavior change support, resulted in modest improvement in low-density lipoprotein cholesterol levels as well as improvement in other cardiovascular risk factors. In an Editorial, Eapen and Peterson discuss the need for evidence that mobile technologies can facilitate improvements in health.

After patients survive an in-hospital cardiac arrest, discussion should focus on prognosis and preferences for future resuscitative efforts. In an analysis of data from 26 327 patients who were successfully resuscitated after an in-hospital cardiac arrest, Fendler and colleagues found that although do-not-resuscitate (DNR) orders were generally aligned with patients’ likelihood of favorable neurological survival after cardiac arrest, only one-third of patients with the worst prognosis—an estimated 4% likelihood of favorable neurological survival—had DNR orders. In an Editorial, Angus discusses patient prognosis and decisions regarding care after an in-hospital cardiac arrest.

In a retrospective cohort study involving more than 1.1 million Medicare beneficiaries with pneumonia who were admitted to 2988 acute care hospitals from 2010 to 2012, Valley and colleagues found that compared with general ward admission, ICU admission was associated with improved survival and no significant difference in Medicare spending or hospital costs. In an Editorial, Barbash and Kahn discuss the value of ICU admission for low-risk patients.


An article in JAMA Internal Medicine reported that between 2001 and 2010, a substantial proportion of older adults with diabetes and multiple serious comorbidities or functional limitations achieved tight glycemic control targets—suggesting potential overtreatment. In this From the JAMA Network article, Huang discusses diabetes treatment goals for older patients with multiple coexisting illnesses.

This JAMA Clinical Evidence Synopsis article by Schmidt-Hansen and colleagues summarizes a Cochrane review (17 clinical trials; 1390 patients total) that examined the efficacy and safety of oxycodone compared with placebo or an active drug for cancer pain in adults. The available evidence was of low quality due to methodological quality and small size of the studies. The evidence review found that oxycodone is not associated with better pain relief or fewer adverse events than other strong opioids.

This Medical Letter on Drugs and Therapeutics article provides information about alirocumab, a subcutaneously injected PCSK9 (proprotein convertase subtilisin kexin type 9) inhibitor, which has been approved as an adjunct to diet and maximally tolerated statin therapy for adults with heterozygous familial hypercholesterolemia or individuals with atherosclerotic cardiovascular disease who require additional lowering of low-density lipoprotein (LDL) cholesterol. Efficacy and safety data from clinical trials of alirocumab are summarized.




Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.


Some tools below are only available to our subscribers or users with an online account.

0 Citations

Related Content

Customize your page view by dragging & repositioning the boxes below.